Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery

Journal of Investigative Dermatology

Volumn 131, Issue 4, 2011, Pages 962-968

  Frost, Georgia A ^a   Halliday, Gary M ^a   Damian, Diona L ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DNA DAMAGE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE DEFICIENCY; MALE; NARROW BAND IMAGING; NORMAL HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION MEASUREMENT;

EID: 79952763925     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.429     Document Type: Article

References (48)

1. Babilas P, Landthaler M, Szeimies RM (2006) Photodynamic therapy in dermatology. Eur J Dermatol 16:340-8 (Pubitemid 44328972)
2. Bouros D, Zeros G, Panaretos C et al. (1991) Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 99:416-9
3. Brown SB, Brown EA, Walker I (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5:497-508 (Pubitemid 39069400)
4. Calzavara-Pinton PG, Venturini M, Sala R (2007) Photodynamic therapy:up-date 2006. Part 1: Photochemistry and photobiology. J Eur Acad Dermatol Venereol 21:293-302
5. Cottrell WJ, Paquette AD, Keymel KR et al. (2008) Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 14:4475-83
6. Damian DL, Halliday GM (2002) Measurement of ultraviolet radiation-induced suppression of recall contact and delayed-type hypersensitivity in humans. Methods 28:34-45
7. De Bruijn HS, Meijers C, van der Ploeg-van den Heuvel A et al. (2008) Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevu-linate. J Photochem Photobiol B 92:91-7
8. De Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A et al. (2006) Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy. Photodermatol Photoimmunol Photomed 22:238-46 (Pubitemid 44317157)
9. De Haas ER, De Bruijn HS, Sterenborg HJ et al. (2008) Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 88:547-54
10. De Haas ER, Kruijt B, Sterenborg HJCM et al. (2006) Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 126:2679-86 (Pubitemid 44764052)
11. Dragieva G, Hafner J, Dummer R et al. (2004) Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 77:115-21 (Pubitemid 38116882)
12. Elmets CA, Bowen KD (1986) Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. Cancer Res 46:1608-11 (Pubitemid 16121476)
13. Ericson MB, Sandberg C, Stenquist B et al. (2004) Photodynamic therapy of actinic keratosis at verying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 151:1204-12 (Pubitemid 40030168)
14. Fitzpatrick TB (1998) The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 124:869-71
15. Foster TH, Murant RS, Bryant RG et al. (1991) Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 126:296-303
16. Fritsch C, Homey B, Stahl W et al. (2000) Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 68:218-21 (Pubitemid 128472013)
17. Gollnick SO, Musser DA, Oseroff AR et al. (2001) IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response. Photochem Photobiol 74:811-6
18. Haller JC, Cairnduff F, Slack G et al. (2000) Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol 143:1270-5
19. Halliday GM (2010) Common links among the pathways leading to UV-induced immunosuppression. J Invest Dermatol 130:1209-12
20. Haylett AK, Ward TH, Moore JV (2003) DNA damage and repair in Gorlin syndrome and normal fibroblasts after aminolevulinic acid photodynamic therapy: a comet assay study. Photochem Photobiol 78: 337-41
21. Henderson BW, Gollnick SO, Snyder JW et al. (2004) Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Research 64:2120-6 (Pubitemid 38339462)
22. Hilf R (2007) Mitochondria are targets of photodynamic therapy. J Bioenerg Biomembr 39:85-9 (Pubitemid 46877177)
23. Iinuma S, Schomaker KT, Wagnieres G et al. (1999) In vivo fluence rate and fractionation effects on tumor response and photobleaching: photo-dynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res 59:6164-70 (Pubitemid 30035638)
24. Javeri A, Huang XX, Bernerd F et al. (2008) Human 8-oxoguanine-DNA glycosylase 1 protein and gene are expressed more abundantly in the superficial than basal layer of human epidermis. DNA Repair (Amst) 7:1542-50
25. Juzeniene A, Juzenas P, Ma ZL et al. (2006) Topical application of 5-aminolaevulinic acid, methyl 5-aminolaevulinate and hexyl 5-amino-laevulinate on normal human skin. Br J Dermatol 155:791-9 (Pubitemid 44352561)
26. Kousis PC, Henderson BW, Maier PG et al. (2007) Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res 67:10501-10 (Pubitemid 350070826)
27. Kozmin S, Slezak G, Reynaud-Angelin A et al. (2005) UVA radiation is highly mutagenic in cells that are unable to repair 7,8-dihydro-8-oxoguanine in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 102:13538-43 (Pubitemid 41420884)
28. Kuchel JM, Barnetson RS, Halliday GM (2005) Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem Photobiol Sci 4:577-82 (Pubitemid 41176272)
29. Langmack K, Mehta R, Twyman P et al. (2001) Topical photodynamic therapy at low fluence rates-theory and practice. J Photochem Photobiol B 60:37-43 (Pubitemid 32401360)
30. Lesar A, Ferguson J, Moseley H (2009) A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. Photodermatol Photoimmunol Photomed 25:191-5
31. Matthews YJ, Damian DL (2010) Topical photodynamic therapy is immuno-suppressive in humans. Br J Dermatol 162:637-41
32. Morton C, Horn M, Leman J et al. (2006) Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 142:729-35
33. Morton CA, Brown SB, Collins S et al. (2002) Guidelines for topical photodynamic therapy: report of a workshop of the British Photoderma-tology Group. Br J Dermatol 146:552-67 (Pubitemid 34437765)
34. Morton CA, McKenna KE, Rhodes LE (2008) Guidelines for topical photodynamic therapy: update. Br J Dermatol 159:1245-66
35. Moseley H, Allen JW, Ibbotson S et al. (2006) Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. Br J Dermatol 154:747-50 (Pubitemid 43374104)
36. Rhodes LE, De Rie MA, Leifsdottir R et al. (2007) Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photo-dynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 143:1131-6 (Pubitemid 47443364)
37. Robinson DJ, De Bruijn HS, van der Veen N et al. (1998) Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol 67:140-9 (Pubitemid 128471972)
38. Singh G, Alqawi O, Espiritu M (2010) Metronomic PDT and cell death pathways. Methods Mol Biol 635:65-78
39. Sitnik TM, Henderson BW (1998) The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 67:462-6 (Pubitemid 128472703)
40. Sreevidya CS, Fukunaga A, Khaskhely NM et al. (2010) Agents that reverse UV-Induced immune suppression and photocarcinogenesis affect DNA repair. J Invest Dermatol 130:1428-37
41. Szeimies RM (2007) Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 25:89-94
42. Takahashi H, Nakajima S, Sakata I et al. (2005) ATX-S10(Na)-photodynamic therapy is less carcinogenic for mouse skin compared with ultraviolet B irradiation. Br J Dermatol 153:1182-6 (Pubitemid 41779574)
43. Tschen EH, Wong DS, Pariser DM et al. (2006) Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol 155:1262-9 (Pubitemid 44730005)
44. Varma S, Holt PJ, Anstey AV (2000) Erythroplasia of queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 142:825-6 (Pubitemid 30226411)
45. Wiegell SR, Haedersdal M, Philipsen PA et al. (2008) Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 158:740-6 (Pubitemid 351415748)
46. Wolf P, Fink-Puches R, Reimann-Weber A et al. (1997) Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 194:53-4 (Pubitemid 27047333)
47. Wulff BC, Schick JS, Thomas-Ahner JM et al. (2008) Topical treatment with OGG1 enzyme affects UVB-induced skin carcinogenesis. Photochem Photobiol 84:317-21 (Pubitemid 351421383)
48. Yao Y, Wolverton JE, Zhang Q et al. (2009) Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species. J Immunol 182:2842-8